South Korean regenerative medicine startup YiPSCELL has received a domestic decision to register a patent covering low-immunogenic universal induced pluripotent stem cells (iPSCs), expanding its cell therapy strategy. The October 14, 2026 decision covers engineering and manufacturing methods intended to reduce immune recognition. The technology could support its therapies, cell line supply business, and partnerships.
A Selective Approach to Immune Recognition
Donor-derived cell therapies can trigger immune responses when a patient's immune system identifies transplanted cells as foreign, challenging treatments intended for many patients. YiPSCELL selectively edits human leukocyte antigen (HLA) genes involved in immune recognition. Its objective is to develop cell sources that could serve multiple recipients with less reliance on donor matching.
The technology reduces HLA-A, HLA-B, and HLA-DRA expression while maintaining HLA-C, B2M, and CIITA levels. Targeting HLA-DRA is an important feature because it encodes a shared component of immune-related HLA-DR molecules. This selective strategy seeks to limit immune recognition while preserving other immune-related features.
Research Establishes an Experimental Foundation
The supporting research appeared in Experimental & Molecular Medicine on March 14, 2025. Researchers used CRISPR-Cas9 editing to generate iPSC lines with disruptions in three HLA genes and examined whether modified cells retained stem cell properties. Their findings showed preserved pluripotency, differentiation potential, and genetic stability in edited cells.
Laboratory tests also found reduced immune-cell responses to the edited cell line compared with unmodified cells in laboratory conditions. The findings support potential use in allogeneic therapy, which treats recipients using donor cells. However, laboratory findings cannot establish clinical safety, effectiveness, or universal compatibility.
Manufacturing and Quality Systems Take Shape
The research received support through South Korea's Scale-up TIPS initiative, linking private investment with government research funding. YiPSCELL has pursued low-immunogenic cells and next-generation cartilage therapies. Its work now includes reproducible manufacturing and quality control.
YiPSCELL says it has secured good manufacturing practice-grade gene-editing plasmids and developed universal iPSC production procedures. It has also established systems to assess genetic stability and perform quality testing on manufactured cell lines. These steps are intended to provide a more consistent manufacturing foundation for future development and applications.
Cell Line Contracts Support Commercial Expansion
Commercial efforts span cell line distribution, joint development, and manufacturing services. In 2025, YiPSCELL signed agreements with Asan Medical Center, Etyxstem, and Celloid worth approximately 6 billion won, including milestones. Payments are tied to progress in subsequent research and development.
Separately, YiPSCELL reported 2 billion won in cell line supply revenue over three years. YiPSCELL sees opportunities to extend the platform through technology licensing and partnerships with organizations developing cell-based treatments. These figures concern existing operations, not sales of therapies using the technology addressed by the patent decision.
A Separate Next-Generation Therapy Program
YiPSCELL is already conducting clinical research involving MIUChon, its iPSC-based treatment candidate for osteoarthritis, alongside supplying clinical-grade iPSCs. The universal iPSC technology is intended to support a separate, next-generation cartilage therapy program separately from MIUChon's clinical research. Wider applications require validation of differentiated cells for specific diseases.
The patent decision advances YiPSCELL's effort to commercialize its stem cell platform. Its gene editing, manufacturing systems, and partnerships could support applications beyond cartilage treatment. Clinical validation and reliable manufacturing remain essential to demonstrate broader therapeutic potential.